THz metamaterial microfluid system with MXene coating

Abstract

The utility model discloses an MXene coating THz metamaterial microfluid system which comprises a sample separation module, a nucleic acid amplification module and an MXene coating THz metamaterial microfluid chip, wherein the sample separation module, the nucleic acid amplification module and the MXene coating THz metamaterial microfluid chip are controlled by a valve; the sample separation module comprises an exosome capture unit and an RNA extraction area, and the exosome capture unit is used for exosome splitting decomposition and RNA extraction; the nucleic acid amplification module is provided with a microRNA isothermal amplification system; the MXene coating THz metamaterial microfluidic chip is composed of an array metamaterial with a surface coating MXene material, the array metamaterial is provided with periodically arranged metal opening resonance rings, the electric field intensity of THz waves during SDA product surface characteristic resonance can be increased to the maximum extent, and miniaturized, integrated, automatic, high-sensitivity and high-throughput combined detection of multiple microRNA molecules is achieved.

Description

Technical Field

[0001] This utility model relates to a detection device, specifically to an MXene-coated THz metamaterial microfluidic system. Background Technology

[0002] Heart failure (HF), the end-stage of various critical cardiovascular diseases, is one of the most common causes of hospitalization in people over 65 years of age. Given its high hospitalization, morbidity, and mortality rates, early warning and risk assessment of HF are crucial for guiding treatment decisions and improving patient survival. HF biomarkers, including plasma B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP), are important diagnostic tools. While BNP is highly valuable in acute HF, its concentration in non-acute HF is often below the critical value, significantly reducing its diagnostic efficacy in early diagnosis. Although guidelines recommend NT-proBNP as an exclusionary marker for non-acute HF, its difficulty in classifying subtypes such as preserved ejection fraction (HFpEF) or reduced ejection fraction (HFrEF) limits its clinical guidance. MicroRNAs (microRNAs) are a class of endogenous non-coding RNAs involved in multiple HF pathological processes, including cardiomyocyte apoptosis. Multiple clinical studies have shown that abnormal concentrations of various microRNAs, including microRNA-499, microRNA-122, and microRNA-132, can be detected in heart failure patients. Combined diagnosis using multiple microRNAs in the blood and NT-proBNP can significantly improve the specificity and accuracy of early heart failure diagnosis. More importantly, evidence suggests that microRNA profiling can greatly improve the differential diagnosis between HFpEF and HFrEF heart failure, potentially filling the gap in traditional heart failure biomarkers for subtype classification. These findings demonstrate the enormous potential of microRNAs as novel biomarkers for early warning and subtype classification of heart failure. Their highly sensitive detection not only possesses extremely high diagnostic value but also provides guidance for clinical decision-making based on heart failure type, achieving precision treatment and improved prognosis.

[0003] Due to their short chain length, low abundance, and high homology, microRNA detection has always been a challenge in the field of molecular diagnostics. Currently, mature detection technologies mainly include Northern blotting, microarrays, and quantitative real-time PCR. Northern blotting was once considered the standard method, but its sensitivity is low and it requires large sample volumes. Microarrays perform quantitative analysis based on microwell arrays, but their specificity is low due to interference from markers within the wells. Quantitative real-time PCR improves specificity through nucleic acid amplification, but primer design is complex and the amplification process depends on precise temperature control. Although research on microRNA detection based on electrochemical sensing or SPR technology has emerged in recent years, it is difficult to routinely implement in actual clinical practice due to the high cost of instruments and cumbersome operation. Therefore, constructing a rapid, simple, and highly sensitive microfluidic system for the joint detection of microRNA has significant application value for early warning and subtype classification of heart failure. Summary of the Invention

[0004] In view of this, the purpose of this utility model is to provide an MXene-coated THz metamaterial microfluidic system that can achieve high-throughput joint detection of multiple microRNA molecules, providing a tool for early warning and subtype classification of clinical heart failure.

[0005] To achieve the above objectives, this utility model provides the following technical solution:

[0006] 1. An MXene-coated THz metamaterial microfluidic system, the microfluidic system comprising a sample separation module (1), a nucleic acid amplification module (4), and an MXene-coated THz metamaterial microfluidic chip (5) controlled by valves, wherein the sample separation module (1), the nucleic acid amplification module (4), and the MXene-coated THz metamaterial microfluidic chip (5) are connected.

[0007] The sample separation module 1 includes an exosome capture unit (2) and an RNA extraction zone (3). The exosome capture unit (2) and the RNA extraction zone (3) are connected by a valve. The exosome capture unit (2) adopts a polydimethylsiloxane microcolumn structure. The microcolumn is filled with magnetic beads modified with exosome capture agent. The RNA extraction zone (3) is provided with an inlet and an outlet for exosome lysis and is used for exosome lysis and RNA extraction.

[0008] The nucleic acid amplification module (4) is equipped with an inlet and an outlet for the microRNA isothermal amplification system;

[0009] The microfluidic chip (5) with MXene-coated THz metamaterial is composed of an array of metamaterials with MXene coating on the surface. The array of metamaterials is designed with periodically arranged metal open resonant rings. Control valves are set at both ends of the microfluidic chip (5).

[0010] Preferably, the exosome capturing agent of the present invention is a CD63 antibody.

[0011] Preferably, the microRNA isothermal amplification system of the present invention is an isothermal amplification system for microRNA-499, microRNA-124, microRNA-132, microRNA-155 and microRNA-21 heart failure microRNA molecules.

[0012] The beneficial effects of this invention are as follows: This invention combines three major innovations: THz spectroscopy technology, the MXene-coated THz metamaterial strategy, and microfluidic chip integration. THz spectroscopy technology provides the theoretical basis and technical support for microRNA detection; the MXene-coated THz metamaterial strategy combines the dielectric sensing capability of metamaterials with the optical modulation properties of MXene, solving the sensitivity problem of microRNA detection; the microfluidic chip system systematically integrates various modules, providing a corresponding technical platform for rapid, high-throughput joint detection of microRNA molecules. Compared with existing microRNA detection technologies, the MXene-coated THz metamaterial microfluidic system fully leverages the interdisciplinary advantages of molecular biology, nanomaterials science, and physical optics, achieving dual signal amplification while ensuring detection throughput. It realizes the miniaturized, integrated, automated, highly sensitive, and high-throughput joint detection of multiple microRNAs, providing a novel research approach for the application of THz technology in the field of heart failure marker detection. Attached Figure Description

[0013] To make the objectives, technical solutions, and beneficial effects of this utility model clearer, the following drawings are provided for illustration:

[0014] Figure 1 For MXene-coated THz metamaterial microfluidic systems. Detailed Implementation

[0015] The present invention will be further described below with reference to the accompanying drawings and specific embodiments, so that those skilled in the art can better understand and implement the present invention. However, the embodiments are not intended to limit the present invention.

[0016] Example 1: Construction of an MXene-coated THz metamaterial microfluidic system

[0017] The MXene-coated THz metamaterial microfluidic system includes a sample separation module (1) controlled by valves, a nucleic acid amplification module (4), and a microfluidic chip (5) of MXene-coated THz metamaterial;

[0018] The sample separation module 1 includes an exosome capture unit (2) and an RNA extraction zone (3). The exosome capture unit (2) and the RNA extraction zone (3) are connected by a valve. The exosome capture unit (2) adopts a polydimethylsiloxane microcolumn structure. The microcolumn is filled with magnetic beads modified with exosome capture agent. The RNA extraction zone (3) is provided with an inlet and an outlet for exosome lysis buffer, which are used for exosome lysis and RNA extraction.

[0019] The nucleic acid amplification module (4) is equipped with 5 parallel channels. Each channel is an isothermal amplification system for 499, 124, 132, 155, and 215 microRNA molecules for heart failure. The channels are equipped with inlet and outlet ports for the microRNA isothermal amplification system at both ends.

[0020] The microfluidic chip (5) with MXene-coated THz metamaterial consists of an array of metamaterials coated with MXene material and control valves at both ends. The array of metamaterials is designed with periodically arranged metal open resonant rings. The periodically arranged metal open resonant rings of the microfluidic chip (5) can maximize the electric field intensity of the THz wave when the surface features of SDA products resonate, thereby realizing the miniaturization, integration, automation, high sensitivity and high throughput joint detection of various microRNA molecules.

[0021] During the detection process, clinical samples were added to sample separation module 1. In the exosome capture unit (2) of sample separation module 1, magnetic beads modified with exosome capture agent were used to separate and enrich exosomes. Then, the valve between the exosome capture unit (2) and the RNA extraction zone (3) was opened, and the magnetic beads adsorbing exosomes were introduced into the RNA extraction zone (3). Then, exosome lysis buffer was introduced from the inlet of the RNA extraction zone (3) to lyse the exosomes and release the RNA, resulting in a microRNA mixture. The microRNA mixture was then introduced into nucleic acid amplification module (5). Amplification components were added to nucleic acid amplification module (5) for amplification, resulting in amplified microRNA-499, microRNA-124, microRNA-132, microRNA-155, and microRNA-215 molecules. Finally, microRNA-499, microRNA-124, microRNA-132, microRNA-155, and microRNA-215 were detected on a microfluidic chip of MXene-coated THz metamaterial.

[0022] In this invention, the amplification components include microRNA, Temple DNA, Klenow fragment, and Nt.BsmAI; the exosome lysis buffer includes Tris-HCl (pH 7.4), NaCl, 2.5% deoxycholic acid, 10% NP-40, EDTA, SDS, etc.

[0023] The above-described embodiments are merely preferred embodiments provided to fully illustrate the present invention, and the scope of protection of the present invention is not limited thereto. Equivalent substitutions or modifications made by those skilled in the art based on the present invention are all within the scope of protection of the present invention. The scope of protection of the present invention is defined by the claims.

Claims

1. An MXene-coated THz metamaterial microfluidic system, characterized in that: The microfluidic system includes a sample separation module (1) controlled by valves, a nucleic acid amplification module (4), and a microfluidic chip (5) with MXene-coated THz metamaterial; The sample separation module (1) includes an exosome capture unit (2) and an RNA extraction zone (3). The exosome capture unit (2) and the RNA extraction zone (3) are connected by a valve. The exosome capture unit (2) adopts a polydimethylsiloxane microcolumn structure. The microcolumn is filled with magnetic beads modified with exosome capture agent. The RNA extraction zone (3) is provided with an inlet and an outlet for exosome lysis and is used for exosome lysis and RNA extraction. The nucleic acid amplification module (4) is equipped with an inlet and an outlet for the microRNA isothermal amplification system; The microfluidic chip (5) with MXene-coated THz metamaterial is composed of an array of metamaterials with MXene coating on the surface. The array of metamaterials is designed with periodically arranged metal open resonant rings. Control valves are set at both ends of the microfluidic chip (5).

2. The MXene-coated THz metamaterial microfluidic system according to claim 1, characterized in that: The exosome capturing agent is a CD63 antibody.

3. The MXene-coated THz metamaterial microfluidic system according to claim 1, characterized in that: The microRNA isothermal amplification system is an isothermal amplification system for microRNA-499, microRNA-124, microRNA-132, microRNA-155, and microRNA-21 heart failure microRNA molecules.

Images